Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
55 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Pipeline Review, H2 2017 Summary According to the recently published report 'Matrix Metalloproteinase 9 - Pipeline Review, H2 2017'; Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) pipeline Target constitutes close to 18 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Matrix metallopeptidase 9 (MMP-9) is a matrixin that belong to the zinc-metalloproteinases family. It plays an essential role in local proteolysis of the extracellular matrix and in leukocyte migration and bone osteoclastic resorption. MMP9 along with elastase, appears to be a regulatory factor in neutrophil migration across the basement membrane. MMP9 may play an important role in wound repair, angiogenesis and neovascularization. The report 'Matrix Metalloproteinase 9 - Pipeline Review, H2 2017' outlays comprehensive information on the Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 6 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Cardiovascular, Gastrointestinal, Dermatology, Genetic Disorders, Immunology, Musculoskeletal Disorders, Respiratory, Infectious Disease, Male Health, Ophthalmology and Undisclosed which include indications Myocardial Infarction, Neuropathic Pain, Congestive Heart Failure (Heart Failure), Crohn's Disease (Regional Enteritis), Hypertension, Marfan Syndrome, Wounds, Acute Pain, Adenocarcinoma Of The Gastroesophageal Junction, Aneurysm, Cancer Pain, Chronic Obstructive Pulmonary Disease (COPD), Chronic Pain, Cystic Fibrosis, Dupuytren Contracture, Epilepsy, Fibrosis, Gastric Cancer, Herpes Labialis (Oral Herpes), Keratoconjunctivitis sicca (Dry Eye), Liver Fibrosis, Lung Adenocarcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Opium (Opioid) Addiction, Osteoarthritis Pain, Pancreatic Islet Transplant Rejection, Peyronies Disease, Pulmonary Fibrosis, Rheumatoid Arthritis, Solid Tumor, Squamous Non-Small Cell Lung Carcinoma, Stroke, Traumatic Brain Injury and Unspecified. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - The report reviews Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics and enlists all their major and minor projects - The report assesses Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Overview 7 Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Therapeutics Development 8 Products under Development by Stage of Development 8 Products under Development by Therapy Area 9 Products under Development by Indication 10 Products under Development by Companies 12 Products under Development by Universities/Institutes 16 Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Therapeutics Assessment 18 Assessment by Mechanism of Action 18 Assessment by Route of Administration 19 Assessment by Molecule Type 21 Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Companies Involved in Therapeutics Development 23 EA Pharma Co Ltd 23 Gilead Sciences Inc 23 Iproteos SL 24 Shulov Innovative Science Ltd 24 Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Drug Profiles 26 andecaliximab - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 AQU-005 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 AQU-010 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 AQU-118 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 CALY-001 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 IPRO-003 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Monoclonal Antibodies to Inhibit MMP-2 and MMP-9 for Crohn's Disease - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 ND-336 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 ND-478 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Protearin - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Peyronies Disease, Dupuytren Contracture and Pancreatic Islet Transplant Rejection - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Recombinant Protein to Target MMP-9 for Wounds - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 SI-1004 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 SI-1005 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Small Molecule to Inhibit Matrix Metalloproteinase 9 for Oncology - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Small Molecules to Inhibit Carbonic Anhydrases and MMPs for Metastatic Melanoma - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Small Molecules to Inhibit MMP for Myocardial Infarction - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 ZEP-3 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Dormant Products 46 Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Discontinued Products 49 Matrix Metalloproteinase 9 (Gelatinase B or 92 kDa Type IV Collagenase or 92 kDa Gelatinase or MMP9 or EC 3.4.24.35) - Product Development Milestones 50 Featured News & Press Releases 50 Nov 02, 2016: Abzena Provides Update on GS-5745 50 Sep 21, 2016: Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis 50 Jun 28, 2016: NeuroMax Announces Start Phase 1 Clinical Trial of AQU-005 for the Treatment of Neuropathic Pain 50 May 13, 2015: Abzena provides an update on the clinical development of one of the humanized antibodies created using its Composite Human Antibody technology 51 Dec 26, 2011: New Antibodies Treat Autoimmune Disease in Mice 51 Oct 08, 2011: Researchers from Notre Dame university create breakthrough in neurological diseases 52 Oct 06, 2011: Notre Dame researchers make neurological disease breakthrough 53 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 54 Disclaimer 55
List of Tables
Number of Products under Development by Stage of Development, H2 2017 8 Number of Products under Development by Therapy Areas, H2 2017 9 Number of Products under Development by Indications, H2 2017 10 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 11 Number of Products under Development by Companies, H2 2017 12 Products under Development by Companies, H2 2017 13 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 15 Number of Products under Investigation by Universities/Institutes, H2 2017 16 Products under Investigation by Universities/Institutes, H2 2017 17 Number of Products by Stage and Mechanism of Actions, H2 2017 18 Number of Products by Stage and Route of Administration, H2 2017 20 Number of Products by Stage and Molecule Type, H2 2017 22 Pipeline by EA Pharma Co Ltd, H2 2017 23 Pipeline by Gilead Sciences Inc, H2 2017 24 Pipeline by Iproteos SL, H2 2017 24 Pipeline by Shulov Innovative Science Ltd, H2 2017 25 Dormant Products, H2 2017 46 Dormant Products, H2 2017 (Contd..1), H2 2017 47 Dormant Products, H2 2017 (Contd..2), H2 2017 48 Discontinued Products, H2 2017 49
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
